MPL and myelodysplastic syndrome: Further treatments are indicated only in specific subsets (i.e., lenalidomide for 5q- syndromes, luspatercept in MDS with ring sideroblasts (MDS RS), danazol, thrombopoietin receptor analogues, and immunosuppression in thrombocytopenic and hypoplastic cases) and with responses limited in number and duration (1, 4–7).